IRIS
GIULIANO, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.016
EU - Europa 1.235
AS - Asia 965
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 4.259
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.973
IT - Italia 773
SG - Singapore 411
HK - Hong Kong 254
CN - Cina 217
NL - Olanda 125
DE - Germania 81
IE - Irlanda 56
FI - Finlandia 47
CI - Costa d'Avorio 41
CA - Canada 39
VN - Vietnam 36
GB - Regno Unito 29
IN - India 27
FR - Francia 26
SE - Svezia 24
RU - Federazione Russa 16
UA - Ucraina 12
BE - Belgio 8
PK - Pakistan 6
ES - Italia 5
AT - Austria 4
CZ - Repubblica Ceca 4
JP - Giappone 4
PL - Polonia 4
AL - Albania 3
BZ - Belize 3
DK - Danimarca 3
LT - Lituania 3
MY - Malesia 3
RS - Serbia 3
BG - Bulgaria 2
IR - Iran 2
IS - Islanda 2
MK - Macedonia 2
PH - Filippine 2
AM - Armenia 1
AU - Australia 1
EU - Europa 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
MC - Monaco 1
MX - Messico 1
TW - Taiwan 1
Totale 4.259
Salva come PNG Salva come JPEG
Città #
Chandler 426
Singapore 355
Hong Kong 253
Santa Clara 181
Naples 139
Napoli 127
Amsterdam 121
Millbury 113
Ashburn 104
Beijing 66
Princeton 55
Des Moines 52
Nanjing 41
Wilmington 37
Dong Ket 36
Lawrence 34
Boston 28
Pune 25
Ottawa 24
Rome 23
Seattle 21
Milan 20
Jacksonville 17
Casoria 13
Formia 13
Pomigliano d'Arco 13
Toronto 12
Dearborn 11
Nanchang 11
Moscow 10
Jiaxing 9
Shenyang 9
Villaricca 9
Woodbridge 9
Boardman 8
Caserta 8
Hebei 8
Redwood City 8
Tianjin 8
Bologna 7
Changsha 7
Fairfield 7
Kronberg 7
London 7
Salerno 7
Sant'Agnello 7
Massa di Somma 6
Munich 6
Nuremberg 6
Somma Vesuviana 6
Caivano 5
Genoa 5
Guangzhou 5
Los Angeles 5
New York 5
Palermo 5
Shanghai 5
Washington 5
Angri 4
Battipaglia 4
Brescia 4
Brussels 4
Dallas 4
Dublin 4
Falls Church 4
Helsinki 4
Kortrijk 4
Lappeenranta 4
Marano di Napoli 4
Norwalk 4
Portici 4
Sciacca 4
Seregno 4
Veroli 4
Afragola 3
Ancona 3
Augusta 3
Belize City 3
Brno 3
Chiaravalle Centrale 3
Falkenstein 3
Frankfurt am Main 3
Granada 3
Indiana 3
Kuala Lumpur 3
Lahore 3
Luco dei Marsi 3
Menlo Park 3
Pellezzano 3
San Jose 3
Siena 3
Springfield 3
Tirana 3
Vienna 3
Bacoli 2
Carpi 2
Castelnuovo del Garda 2
Changchun 2
Chengdu 2
Duncan 2
Totale 2.706
Salva come PNG Salva come JPEG
Nome #
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 99
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 95
Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review 90
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 84
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 71
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 67
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 67
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 58
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 58
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 57
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 56
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 55
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 54
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 54
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 54
A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA 53
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 52
Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour 52
R0 surgical resection of giant dedifferentiated retroperitoneal liposarcomas in the COVID era with and without nephrectomy: A case report 50
Mechanisms of lapatinib resistance in HER2-driven breast cancer 50
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 50
Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy 49
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 49
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications 49
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 48
Tumori maligni del colon 47
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study 46
Blockade of AP-1 potentiates endocrine therapy and overcomes resistance 46
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 46
Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors 46
Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis 45
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 45
Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide 45
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. 44
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 44
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis 43
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. 43
Circulating tumor cells in newly diagnosed inflammatory breast cancer 43
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives 42
Tumor characteristics and prognosis in familial breast cancer 42
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 42
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug? 41
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis 41
Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction 41
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 40
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 40
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. 39
A djuvant treatment in patients at high risk of recurrence of thymoma: Efficacy and safety of a three-dimensional conformal radiation therapy regimen 39
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? 39
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 39
Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype 38
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination 38
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study 38
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer 38
Boosting the immune response with the combination of electrochemotherapy and immunotherapy: A new weapon for squamous cell carcinoma of the head and neck? 38
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy 38
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase 37
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom? 37
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 36
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. 36
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. 36
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 35
Biological mechanisms and clinical implications of endocrine resistance in breast cancer. 35
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 34
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. 34
Prevalence of Sarcopenia in Women with Breast Cancer 32
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. 32
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. 32
Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer 31
Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report 31
Epigenetic control of gene expression: Potential implications for cancer treatment 31
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis 30
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer 30
Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer 30
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 30
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. 29
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. 29
Mammary Adipose Tissue Control of Breast Cancer Progression: Impact of Obesity and Diabetes 29
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 28
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. 28
Optimal multidisciplinary treatment of oral cavity mucosal melanoma: Outcome analysis in a case series 28
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis 28
Extraskeletal Ewing's sarcoma of the mediastinum: Case report 27
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays? 27
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. 27
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 27
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 26
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 25
Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications. 25
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial 24
Die and let live: harnessing BikDD to combat breast cancer stem cells. 24
Therapeutic potential of the dual EGFR/HER2?inhibitor AZD8931 in circumventing endocrine resistance. 24
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 24
Genetics and management of locally advanced carcinomas of the head and neck: Role of altered fractionation radiotherapy 24
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 23
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial 23
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. 22
Metastasis dormancy in estrogen receptor-positive breast cancer. 22
Immunological signature of patients with thymic epithelial tumors and Good syndrome 22
Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a 21
Totale 4.082
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.219
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.219
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020144 0 0 0 0 0 0 11 18 15 31 54 15
2020/2021276 7 1 26 24 28 18 28 13 49 17 20 45
2021/2022600 9 4 17 9 6 24 14 23 69 60 154 211
2022/20231.005 97 89 37 64 128 104 18 95 146 150 53 24
2023/2024787 33 120 96 51 42 102 11 75 23 24 130 80
2024/20251.130 168 176 14 104 125 224 319 0 0 0 0 0
Totale 4.510